Skip to content
General News, Medical Health Aged Care

Recommended listing of new drug offers hope to those living with metastatic breast cancer

Breast Cancer Network 2 mins read

Breast Cancer Network Australia (BCNA) has welcomed today’s decision to recommend a new targeted treatment for metastatic breast cancer for PBS subsidy.

 

Clinical trials show the new medicine TRUQAP® (capivasertib), in combination with hormone blocking treatment fulvestrant, keeps cancer from growing or spreading for more than twice as long than fulvestrant alone.

 

The drug has been recommended for PBS subsidy for the treatment of HR+ / HER2- locally advanced or metastatic breast cancer, following recurrence or progression on or after endocrine therapy.

 

Vicki Durston, BCNA Director of Policy, Advocacy and Support Services, said this has been a long-awaited outcome.

“It is imperative people with metastatic breast cancer, a growing group with significant unmet needs, have timely access to new and innovative therapies.”

“We have been pleased to hear from consumers and clinicians alike that a previously cost prohibitive treatment will be within reach for people with metastatic disease who do not have time to wait.”

“We welcome people living with metastatic breast cancer having another affordable treatment option that can extend their lives. They often face significant out of pocket costs for these drugs prior to them being subsided – and many cannot afford them at all,” Ms Durston said. 

 

Nurse Practitioner Jenny Gilchrist said the PBAC recommendation of TRUQAP® (capivasertib), in combination with fulvestrant, would help to shift metastatic breast cancer from a treatable but incurable diagnosis to a manageable chronic condition. 

“Capivasertib represents a significant advancement for eligible metastatic breast cancer patients, doubling progression-free survival when combined with fulvestrant.”

 

BCNA will continue to work with both the pharmaceutical company and government to ensure TRUQAP® (capivasertib), is listed on the PBS as soon as possible. 

 

For support and more information about breast cancer, call BCNA’s Helpline on 1800 500 258 or visit bcna.org.au. 


About us:

Breast Cancer Network Australia (BCNA) is Australia’s leading breast cancer consumer organisation. BCNA provides information and support to those diagnosed and their supporters, opportunities to connect with others going through a similar situation and work to influence a stronger healthcare system to ensure all Australians affected by breast cancer receive the very best care, treatment and support.


Contact details:

To arrange  a media interview or comment please contact:
Edwina Pearse
Breast Cancer Network Australia
0417 303 811
[email protected]

 

More from this category

  • Medical Health Aged Care
  • 17/12/2025
  • 13:11
GE HealthCare

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases.…

  • Contains:
  • General News, Travel Tourism
  • 17/12/2025
  • 13:03
Mount Isa Mines Rodeo presented by Akubra

From the red dirt to the rodeo record books: Mount Isa Mines Rodeo 2026 tickets on sale early – December 18

From the red dirt to the rodeo record books: Mount Isa Mines Rodeo 2026 tickets on sale early – December 18 The legendary Mount…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/12/2025
  • 12:03
Jane Morgan Management

LTR Pharma surpasses 1,000 SPONTANĀ® prescriptions under TGA Special Access Scheme

Highlights More than 1,000 SPONTAN® prescriptions issued under the TGA Special Access Scheme Growing prescriber network with continued uptake in complex ED cases, including post-prostate cancer patients Real-world insights informing US commercial strategy ahead of ROXUS® launch in H1 CY2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that more than 1,000 SPONTAN® prescriptions have now been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category B). SPONTAN is being prescribed for patients with unmet clinical needs, including men who have not achieved adequate benefit from traditional oral PDE5 inhibitor…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.